Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
96 hedge funds and large institutions have $263M invested in Bellicum Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 10 closing their positions.
210% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 10
59% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 22
20% more funds holding
Funds holding: 80 → 96 (+16)
1% less capital invested
Capital invested by funds: $266M → $263M (-$2.99M)
79% less call options, than puts
Call options by funds: $350K | Put options by funds: $1.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.9M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$12M |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
+$3.54M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3M |
| 5 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$10.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.55M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.62M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.57M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$998K |
BLCM Hedge Fund Activity: Q1 2017 in Review
96 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2017, worth a combined $263M — down 1.1% from $266M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BLCM positions and 10 closed out — a net gain of 21 holders — while 35 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $21.9M. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $10.6M sold.
- 96 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2017, up from 80 in Q4 2016.
- Funds reported $263M of Bellicum Pharmaceuticals, Inc. stock for Q1 2017, down 1.1% quarter-over-quarter.
- 31 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2017 and 10 closed out, a net change of +21 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $21.9M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2017 was First Eagle Investment Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2017.